Search Results
You are looking at 1 - 3 of 3 items for
- Author: M. J. Whittle x
- Refine by access: All content x
Search for other papers by S P Kirk in
Google Scholar
PubMed
Search for other papers by M A Whittle in
Google Scholar
PubMed
Search for other papers by J M Oldham in
Google Scholar
PubMed
Search for other papers by P M Dobbie in
Google Scholar
PubMed
Search for other papers by J J Bass in
Google Scholar
PubMed
Abstract
GH enhances skeletal muscle growth, and IGF-II peptide is highly expressed during regeneration. We have therefore investigated the effect of GH administration on IGF-II binding and expression in regenerating rat skeletal muscle using the techniques of receptor autoradiography and in situ hybridisation. Notexin, a myotoxin, was injected into the right M. biceps femoris (day 0), causing affected fibres to undergo necrosis followed by rapid regeneration. Animals were administered either GH (200 μg/100 g body weight) or saline vehicle daily. Contralateral muscles were used as regeneration controls. GH administration during regeneration resulted in significant increases in body weight, and damaged and undamaged muscle weights (P<0·001). IGF-II expression, which was examined in regenerating fibres, survivor fibres and undamaged fibres, varied according to tissue type (P< 0·001). Specifically, IGF-II expression in regenerating fibres was elevated relative to control and survivor fibres after day 3 (P<0·05), with a peak on day 9 (P<0·001). GH did not affect IGF-II message levels. 125I-IGF-II binding in regenerating muscle was examined in the same fibre types as well as in connective tissue. 125I-IGF-II binding in regenerating fibres was higher (P<0·001) than in other tissue types on day 5. GH administration increased 125I-IGF-II binding in all damaged muscle tissues on day 5 (P<0·001, regenerating fibres; P<0·01, others). We believe that this shows for the first time an effect of GH on the Type 2 IGF receptor in regenerating skeletal muscle.
Journal of Endocrinology (1996) 149, 81–91
Search for other papers by J. McQueen in
Google Scholar
PubMed
Search for other papers by J. C. P. Kingdom in
Google Scholar
PubMed
Search for other papers by A. G. Jardine in
Google Scholar
PubMed
Search for other papers by J. M. C. Connell in
Google Scholar
PubMed
Search for other papers by M. J. Whittle in
Google Scholar
PubMed
ABSTRACT
Receptors for angiotensin II (AII) and atrial natriuretic peptide (ANP) were characterized in a membrane fraction from resistance-type artery from human placentae. Placentae from normal pregnancies and pregnancies complicated by intrauterine growth retardation (IUGR) were studied. High- and low-affinity receptors for AII (dissociation equilibrium constant (K d) 1 ·7 and 15·7 nmol/l respectively) and ANP (K d 0·2 and 55·5 nmol/l respectively) were identified; these parameters were unchanged in IUGR, but there was a reduction in high-affinity receptor number by approximately 50% for AII and 80% for ANP in this condition. Both peptides may have a role in the regulation of fetoplacental blood flow. The alterations in IUGR are consistent with sustained activation of the fetal reninangiotensin system and suggest altered vascular responsiveness to ANP.
Journal of Endocrinology (1990) 126, 341–347
Search for other papers by S J Bowden in
Google Scholar
PubMed
Search for other papers by J F Emly in
Google Scholar
PubMed
Search for other papers by S V Hughes in
Google Scholar
PubMed
Search for other papers by G Powell in
Google Scholar
PubMed
Search for other papers by A Ahmed in
Google Scholar
PubMed
Search for other papers by M J Whittle in
Google Scholar
PubMed
Search for other papers by J G Ratcliffe in
Google Scholar
PubMed
Search for other papers by W A Ratcliffe in
Google Scholar
PubMed
Abstract
Parathyroid hormone-related protein (PTHrP), the hypercalcaemia of malignacy factor, is expressed in the tissues of the human uteroplacental unit, including the placenta, amnion and chorion. We have used three region-specific immunoassays to quantitate and compare the distribution of PTHrP in tissues obtained at term following spontaneous labour and vaginal delivery or elective Caesarean section. In non-labouring women highest PTHrP(1–86) and (37–67) immunoreactivity was found in amnion covering the placenta, rather than the decidua parietalis of the uterus (reflected amnion) (median 1020 vs 451 fmol/g; 2181 vs 1444 fmol/g respectively). In labouring women, the PTHrP(1–86) concentration in reflected amnion was inversely correlated with the interval between rupture of the membranes and delivery. Tissue PTHrP(1–86) concentrations were lower in placenta than in chorion and amnion (medians 12, 109 and 664 fmol/g respectively) and, in all tissues, PTHrP(1–34) and (37–67) concentrations were significantly higher than that of PTHrP(1–86). Bioactive PTHrP(1–34) was detected in placenta, chorion and amnion using the ROS cell bioassay. The PTHrP(1–86) concentration (mean ± s.e.m.=41·4 ± 4·5 pmol/l) was high in amniotic fluid at term, although in maternal and cord plasma levels were only modestly increased. The molecular forms of PTHrP present in tissues and amniotic fluid were investigated by column chromatography which confirmed its molecular heterogeneity and suggested that processing is tissue-specific and occurs at both amino- and carboxy-terminals of the peptide.
Journal of Endocrinology (1994) 142, 217–224
